CP and chronic myelogenous leukemia, BCR-ABL1 positive: Approximately half of CML-CP (56%) and CML-AP (47%) patients required a reduction in the number of dosing days per cycle (for any reason) during induction; during maintenance cycles, 75% and 64%, respectively, required a reduced number of dosing days [Table II].